DrugPatentWatch Database Preview
CUBICIN RF Drug Profile
Which patents cover Cubicin Rf, and when can generic versions of Cubicin Rf launch?
Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in nineteen countries.
The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
Summary for CUBICIN RF
| International Patents: | 30 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 10 |
| Clinical Trials: | 8 |
| Patent Applications: | 2 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CUBICIN RF at DailyMed |
Pharmacology for CUBICIN RF
| Drug Class | Lipopeptide Antibacterial |
Medical Subject Heading (MeSH) Categories for CUBICIN RF
Synonyms for CUBICIN RF
| 103060-53-3 |
| Cidecin |
| CS-1857 |
| Cubicin |
| Cubicin (TN) |
| D01080 |
| D4229 |
| Dapcin |
| Daptomicina |
| Daptomicina [Spanish] |
| DAPTOMYCIN |
| Daptomycin (JAN/USAN/INN) |
| Daptomycin for injection |
| Daptomycine |
| Daptomycine [French] |
| Daptomycinum |
| Daptomycinum [Latin] |
| Deptomycin |
| HY-B0108 |
| LY 146032 |
| LY-146032 |
| LY146032 |
| MK-3009 |
| MolPort-046-033-485 |
| NWQ5N31VKK |
| SCHEMBL13491700 |
| UNII-NWQ5N31VKK |
US Patents and Regulatory Information for CUBICIN RF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CUBICIN RF
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | ➤ Sign Up |
International Patents for CUBICIN RF
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 102712677 | ➤ Sign Up |
| Chile | 2015002412 | ➤ Sign Up |
| China | 104056250 | ➤ Sign Up |
| Canada | 2781666 | ➤ Sign Up |
| Peru | 15172012 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for CUBICIN RF
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2006 | Austria | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
| C0022 | France | ➤ Sign Up | PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119 |
| C/GB06/024 | United Kingdom | ➤ Sign Up | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
| 2006 00018 | Denmark | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| 22/2006 | Austria | ➤ Sign Up | PRODUCT NAME: DAPTOMYCIN |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
